Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CAEL-101 plus CyBorD versus placebo plus CyBorD in treatment-naive Mayo stage IIIb AL amyloidosis
2022-503073-11-00Phase 3Authorised
- Sponsor
- Alexion Pharmaceuticals
- Start
- May 2024
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 19
01
Overview
Phase 3, randomised, double-blind trial in light-chain amyloidosis and amyloid cardiomyopathy comparing Anselamimab plus plasma cell dyscrasia treatment with Placebo plus plasma cell dyscrasia treatment (2 arms). Primary endpoints: Hierarchical combination of all-cause mortality and cardiovascular hospitalizations, Treatment-emergent adverse events and 5 more. Planned start May 2024; status: authorised.
02
Drugs
anselamimab
03
Conditions
light-chain amyloidosisamyloid cardiomyopathy
Beyond the preview
Go deeper on 2022-503073-11-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2022-503073-11-00.